Calhex 231 hydrochloride

产品编号 T10666Cas号 2387505-78-2

别名

Calhex 231 hydrochloride is a CaSR inhibitor with the potential for diabetic cardiomyopathy treatment. It blocks Ca2+-induced accumulation of [3H]inositol phosphate (IC50: 0.39 μM in HEK293 cells).

Calhex 231 hydrochloride

产品编号 T10666Cas号 2387505-78-2

Calhex 231 hydrochloride is a CaSR inhibitor with the potential for diabetic cardiomyopathy treatment. It blocks Ca2+-induced accumulation of [3H]inositol phosphate (IC50: 0.39 μM in HEK293 cells).

规格	价格	库存
2 mg	¥ 740	5日内发货
25 mg	¥ 4,930	6-8周
50 mg	¥ 6,410	6-8周
100 mg	¥ 9,710	6-8周

大包装 & 定制

加入购物车

实验操作小课堂

联系我们获取更多批次信息

资源下载

产品操作手册

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性

产品描述	Calhex 231 hydrochloride is a CaSR inhibitor with the potential for diabetic cardiomyopathy treatment. It blocks Ca2+-induced accumulation of [3H]inositol phosphate (IC50: 0.39 μM in HEK293 cells).
靶点活性	CaSR:0.39 μM
体外活性	Calhex 231 could inhibit Itch (atrophin-1 interacting protein 4)-ubiquitin proteasome and TGF-β1/Smads pathways, and then depress the proliferation of cardiac fibroblasts, along with the reduction deposition of collagen, alleviate glucose-induced myocardial fibrosis. Calhex 231 treatment significantly downregulates the CaSR, α-SMA, Col-I/III, MMP2/9 expresses. Calhex231 alleviates high glucose-induced myocardial fibrosis in cardiac fibroblasts [1].
体内活性	In the type 1 diabetic model (T1D) rats, Calhex 231 (4.07 mg/kg; i.p.; daily; for 12 weeks; male Wistar rats) treatment ameliorates diabetic myocardial fibrosis [1].